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Aims Therapeutic use of sulfhydrylated inhibitor S-zofenopril has raised different hypotheses regarding the role played by its
thiol group in the beneficial clinical effects exerted compared with other angiotensin-converting enzyme (ACE) inhibi-
tors.Here, we investigatedhydrogen sulfide (H2S)pathwayas accountable forextra-beneficial effects in vascular function.
Methods
and results
Spontaneously hypertensive rat (SHRs) and control Wistar Kyoto (WKY) rats were treated with either S-zofenopril or
enalapril in vivo. Aorta and carotid were harvested and ex vivo vascular reactivity to acetylcholine (Ach) and L-cysteine
(L-cys) assessed. Cystathionine-b-synthase (CBS), cystathionine-g-lyase (CSE), and 3-mercaptosulfur-transferase
(3MST) expression, as well as H2S levels, were evaluated in both vascular tissues. The vascular response to Ach in
both carotid and aorta was impaired in SHR (30%, P, 0.001). S-zofenopril, but not enalapril, restored this response,
while L-cys-induced relaxation was enhanced. CSE expression in vessels and tissue/plasma H2S levels were restored to
WKY values in SHRs receiving S-zofenopril. In contrast, CBS and 3MST expression were not modified by treatments.
S-zofenoprilat, an active metabolite of S-zofenopril, releases H2S in a ‘cell-free’ assay and it directly relaxed vessels
in vitro in a concentration-dependent manner (P, 0.001). In vivo administration of R-zofenoprilat diasteroisomer,
which does not inhibit ACE, did not modify blood pressure; nonetheless, it retained the beneficial effect on SHR vascular
function as well as restored plasma/tissue H2S levels.
Conclusion Our findings establish that S-zofenopril improves vascular function by potentiating the H2S pathway in a model of spon-
taneous hypertension. This novel mechanism, unrelated to ACE inhibition and based on H2S release, could explain the
beneficial effects of sulfhydrylated ACE inhibitors reported in the clinical literature.
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1. Introduction
Angiotensin-converting enzyme (ACE) activation, with consequent
release of angiotensin II, is not only involved in controlling blood pres-
sure, but also contributes to cardiovascular disease by directly acting
on tissues, including remodelling and inflammation.1 Tissue ACE repre-
sents an important therapeutic target and its inhibitioncan restoreendo-
thelial function and/or prevent endothelial dysfunction.2 Indeed, though
ACE can be isolated from plasma, it is also located on the endothelium,
where it is anchored to the plasma membrane and is referred to as
tissue ACE.3 ACE inhibitors (ACEis) are usually classified into three
main groups: sulfhydryl-, dicarboxylate-, and phosphonate-containing
agents.4,5 Within the class of sulfhydryl-containing agents, there are
only twodrugs, captopril and zofenopril.Over the last decade, several clin-
ical papers have shown that sulfhydrylated ACEi zofenopril has additional
beneficial actions compared with dicarboxylate-containing agents. For
instance, zofenopril improves the clinical outcomes of patients with differ-
ent cardiovascular diseases, including acute myocardial infarction and
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congestive heart failure.6–8 Furthermore, the beneficial effects of zofeno-
pril in endothelial dysfunction following heart failure were more evident
compared with the non-sulfhydrylated ACEi lisinopril.9 Interestingly, in a
clinical comparative study, it has been demonstrated that zofenopril, but
not ramipril or atenolol, improves flow-mediated dilation.10 However,
the antioxidant actions of sulfhydrylated ACEi, often ascribed to the pres-
ence of a thiol group,11 per se, does not provide a full explanation for the
additional beneficial effects associated with its use in therapy.12 It is import-
ant tobear in mind that zofenopril is a pro-drug since, in vivo, it is converted,
within the tissue, to zofenoprilat, the active form.7 In addition, it has been
demonstrated that tissue ACE has more impact in the antihypertensive
effect of ACEi13–16compared with serum enzyme isoform. Thus, all
these findings confirm that, at tissue level, a local tuning of angiotensin II
production exists, as well as regulation of blood pressure and vascular re-
activity. It is important to underline that the interaction between ACE and
S-zofenoprilat is stereospecific. Indeed, ACE inhibition only occurs with
S-zofenoprilat, while R-zofenoprilat fails to block ACE activity17 (see Sup-
plementary material online, Figure S1). For this reason, S-zofenopril is the
only isomer used in clinic. The chemical structure of S-zofenoprilat with
a free thiol (Figure1) leadsus tohypothesize that itmight act asanhydrogen
sulfide (H2S) donor in vivo following the metabolism of the parent drug
zofenopril.
H2S has emerged as a novel gaseous mediator involved in vascular
homeostasis.18,19 It is endogenously formed in mammalian cells from
L-cysteine (L-cys) through the action of cystathionine-b-synthase (CBS)
and cystathionine-g-lyase (CSE), both pyridoxal-phosphate-dependent
enzymes. Alternatively, these enzymes can also utilize L-methionine
and/or homocysteine as substrates to produce H2S through different
pathways.20 CBS and CSE are widely distributed and, at the present
stage, CBS-derived H2S acts mainly as a neuromodulator. Conversely,
CSE-derived H2S is mostly involved in vascular homeostasis.
21,22
H2S can also act indirectly at vascular level by activating the eNOS/
cGMP pathway potentiating the effects of NO through different
mechanisms.23–25
Recent generation of mice lacking CSE gene has further highlighted
the role of H2S in vascular homeostasis, since its genetic deletion
results in hypertension.26
Here,we assessedwhether the H2S pathway is involved in theaddition-
albeneficial propertiesexhibitedbyzofenopril. In addition,wehave tested
the effect of active metabolite of zofenopril, e.g. S-zofenoprilat, and com-
pared it with its inactive diastereoisomer R-zofenoprilat.
2. Materials and methods
2.1 Drugs and reagents
All reagents forKrebs’ solutionpreparationwerepurchased fromCarloErba
Reagents (Milano, Italy). Phenylephrine (PE), acetylcholine (Ach), L-cys,
Tris–HCl, Triton, sodium deoxycholate, sodium chloride, EDTA, phenyl-
methanesulfonylfluoride, aprotinin, leupeptin, sodium fluoride, and
pyridoxal-5′-phosphate were purchased from Sigma-Aldrich (Milano,
Italy).Zofenoprilwasusedas calciumsalt, the activemetabolite diastereoiso-
mer, e.g. S,S,S-zofenoprilat and its inactive metabolite diastereoisomer
S,S,R-zofenoprilat, were both used as sodium salt (Figure 1). For brevity,
S,S,S-zofenoprilat and S,S,R-zofenoprilat will be referred to as S-zofenoprilat
andR-zofenoprilat, respectively, throughout the manuscript. Enalapril and its
active metabolite enalaprilat (Figure 1) were used as a non-sulfhydrylated
ACEi control. All ACEis were supplied by the Menarini Research Group
(Firenze, Italy).
Figure1 The structures of (A) zofenopril, (B) zofenoprilat, (C) enalapril, and (D) enalaprilat are reported. The S,S,S-zofenopril is the only diasteroisomer
currently used in clinic. In A and B, the asterisks denote the S configurations at the chiral centres. The arrow denotes the only carbon atom whose config-
uration leads to S,S,S-zofenopril(at) or S,S,R-zofenoprilat. S,S,S-zofenopril(at) and S,S,R-zofenoprilat are referred to as S-zofenopril(at) and R-zofenoprilat,
respectively.
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2.2 Systolic blood pressure measurement and
drug treatment in vivo in SHRs andWKY rats
Male spontaneously hypertensive rats (SHRs) and control Wistar Kyoto
(WKY) rats (8 weeks) were purchased from Charles-River and kept in an
animal care facility under controlled temperature, humidity, and light/dark
cycle and with food and water ad libitum. Rat systolic blood pressure (SBP)
was monitored in conscious animals twice a week by using a BP Recorder
58500 (Ugo Basile, Milano, Italy) in an ad hoc pre-warmed room within the
animal care facility. All animal procedures were performed according to
the ARRIVE guidelines and authorized by Centro Servizi Veterinari Univer-
sita` degli Studi di Napoli ‘Federico II’.
SBP was monitored for 4–6 weeks until hypertension developed in SHR,
and a statistical difference (P, 0.05) in pressure values was reached
between SHR and WKY. Rats were divided into six different treatment
groups (n ¼ 10 for each) and organized as follows:
– SHR: (i) vehicle, (ii) S-zofenopril, and (iii) enalapril.
– WKY: (i) vehicle, (ii) S-zofenopril, and (iii) enalapril.
Rats received zofenopril or enalapril at doses of 10 or 6 mg/kg, respectively,
administered daily for 2 weeks in 0.2% carboxymethylcellulose, per gavage.
SBPwasmonitoredduring the treatment. After2weeks, animals were anaes-
thetized with enflurane (5%) and then euthanized in a CO2 chamber (70%).
Carotid and aorta were harvested and ex vivo vascular reactivity assessed.
Furthermore, blood samples were collected by cardiac puncture in order
to measure H2S levels and ACE activity (see Supplementary material online).
In another set of experiments, we evaluated blood pressure changes fol-
lowing treatment in vivo daily for 14 days with either S-zofenoprilat (10 mg/
kg) or its inactive epimer R-zofenoprilat (10 mg/kg).17 At the end of the ex-
perimental period, rats were sacrificed and aorta and carotid harvested as
described above and vascular reactivity assessed. Blood samples were col-
lected by cardiac puncture in order to measure H2S levels and ACE activity
(see Supplementary material online).
2.3 In vitro study
SHRs and WKY rats were sacrificed, and aorta tissue was harvested to assess
vascular response to direct administration of S-zofenoprilat or enelaprilat to
organ bath and concentration response curves for S-zofenoprilat or enala-
prilat were performed within the range 100 nmol/L–1 mmol/L.
2.4 Vascular reactivity assessment
Rings from aorta (3 mm length) and carotid (1.5 mm length) arteries
were mounted in an isolated organ bath system filled with Krebs’ solution
(mmol/L: 115.3 NaCl, 4.9 KCl, 1.46 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0
NaHCO3, and 11.1 glucose) at 378C and gassed with O2/CO2 mixture
(95/5%). Organ baths were equipped with a force transducer (FORT10,
Ugo Basile) connected to a PowerLab acquisition data system (ADInstru-
ments, Colorado Springs, CO, USA). The rings were stretched until
resting tension was reached and allowed to equilibrate for at least 40 min;
over this period, tension was adjusted, as necessary, to the resting tension
and bathing solution was periodically changed. In each experiment, rings
were first challenged with PE (1 mM) until the responses were reproducible.
The rings were then washed and contracted with PE (1 mM) and, once a
plateau was reached, a cumulative concentration–response curve of Ach
(0.1 nmol/L–30 mmol/L) or L-cys (0.1 mmol/L–10 mmol/L) wasperformed.
2.5 Western blot analysis
Vascular tissues harvested from both WKY rats and SHRs following in vivo
treatment with enalapril and zofenopril were homogenized in RIPA buffer
(50 mmol/L Tris–HCl, pH 7.4, 1% v/v Triton, 0.25% w/v sodium deoxycho-
late, 150 mmol/L sodium chloride, 1 mmol/L ethylenediaminetetraacetic
acid (EDTA), 1 mmol/L phenylmethanesulfonylfluoride, 10 mg/mL aproti-
nin, 20 mmol/L leupeptin, and 50 mmol/L sodium fluoride). Denatured pro-
teins (40 mg) were separated on 10% sodium dodecylsulfate polyacrylamide
gels and transferred to the polyvinylidene fluoride membrane. Membranes
were blocked in phosphate-buffered saline containing 0.1% v/v Tween-20
(PBST) and 3% w/v non-fat dry milk for 30 min, followed by overnight incu-
bation at 48C with rabbit polyclonal CBS (1 : 1000), or mouse monoclonal
CSE (1 : 500) antibody (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany). Rabbit polyclonal 3MST (1 : 500) antibody was purchased from
Abnova (Heidelberg, Germany). Mouse anti-ACE antibody was also tested
(1 : 500, Santa Cruz Biotechnology, Inc.). Membranes were extensively
washed in PBST prior to incubation with horseradish peroxidase-conjugated
secondary antibody for 2 h. Following incubation, membranes were washed
and developed using ImageQuant-400 (GE Healthcare, USA). The target
protein band intensity was normalized over the intensity of the housekeep-
ing protein b-actin (1 : 5000, Sigma-Aldrich)
2.6 H2s quantification assays
2.6.1 Methylene blue assay
Tissue H2S production rate was measured using Stipanuk and Beck based
assay with modifications.18,27,28 Briefly, vessels were homogenized in lysis
buffer containing potassium phosphate buffer (100 mmol/L, pH 7.4;
10 mM sodium orthovanadate, and protease inhibitors). Protein concentra-
tion was determined by using the Bradford assay (Bio-Rad Laboratories,
Milano, Italy). Homogenates were added to a reaction mixture (total
volume 500 mL) containing pyridoxal-5′-phosphate (2 mmol/L, 20 mL),
L-cys (10 mmol/L, 20 mL), and saline (30 mL). The reaction was performed
in sealed eppendorf tubes and initiated by transferring tubes from ice to a
water bath at 378C. After 40 min incubation, zinc acetate (1% w/v,
250 mL) was added followed by trichloroacetic acid (10% w/v, 250 mL). Sub-
sequently, N,N-dimethylphenylendiamine sulfate (20 mmol/L, 133 mL) in
7.2 mol/L HCl and FeCl3 (30 mmol/L, 133 mL) in 1.2 mol/L HCl were
added, and solution optical absorbance was measured after 20 min at a
wavelength of 650 nm. All samples were assayed in duplicate and the H2S
concentration was calculated against a calibration curve of NaHS (3.12–
250 mmol/L).
Plasma H2S levels were determined in the absence of L-cys in the reaction
mixture. Results were expressed as mmol/L concentration. H2S determin-
ation in plasma samples was performed as follows: each sample (100 mL)
was added to eppendorf tubes containing trichloroacetic acid (10% w/v,
300 mL), in order to allow protein precipitation. Supernatant was collected
after centrifugation and zinc acetate (1% w/v 150 ml) was then added. Subse-
quently, N,N-dimethylphenylendiamine sulfate (20 mmol/L, 100 mL) in
7.2 mol/L HCl and FeCl3 (30 mmol/L, 133 mL) in 1.2 mol/L HCl were
added to each tube and absorbance measured after 20 min at a wavelength
of 650 nm. All samples were assayed in duplicate, and the H2S concentration
was calculated against a calibration curve of NaHS (3.12–250 mmol/L). All
chemicals used in this assay were purchased at Sigma-Aldrich.
2.6.2 In vitro fluorimetric assay for H2S release
Fluorimetric determination of H2S released by S-zofenoprilat was per-
formed in a cell-free assay according to a method previously described29
with modifications. Briefly, vehicle or the indicated concentration of
S-zofenoprilat was placed in a black 96-well microplate. Hank’s Balanced
Salt Solution (HBSS, Cat. No. 14025, Invitrogen, at pH 7.4) containing dibro-
mobimane (250 mmol/L) was then added into the well, and fluorescence was
measured immediately in a plate reader at 360/465 nm excitation/emission
(GENios, Tecan) every 1 min over a 30-min period. The amount of H2S
(measured as thiobimane) was expressed as relative fluorescence
unit(RFU). In experiments designed to quench H2S, haemoglobin
(10 mmol/L) was mixed with S-zofenoprilat before adding dibromobinane.
All reactions were performed in triplicate.
2.6.3 In vitro amperometric assay for H2S release
The amperometric assay was performed in a cell-free assay by using an
Apollo-4000 Free Radical Analyzer detector (WPI) and 2 mm H2S-selective
minielectrodes.30 Assay buffer was prepared according to the manufacturer’s
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instructions. The minielectrode was equilibrated in 10 mL of assay buffer,
until a stable baseline was achieved. Then, 100 mL of an aqueous solution
of S-zofenoprilat was added (final concentration 1 mmol/L). The H2S gener-
ation was monitored for 20 min. L-Cys (4 mmol/L) was added prior to
S-zofenoprilat, according to experimental protocol requirements. H2S con-
centration was determined against a calibration curve obtained plotting
amperometric currents (recorded in nA) vs. increasing concentrations of
NaHS (1, 3, 5, and 10 mmol/L) at pH 4.0.
2.7 Statistical analysis
All data were expressed as mean+ SEM. Statistical analysis was performed
by using one-way analysis of variance (ANOVA) and Dunnet as post-test, or
two-way ANOVA and Bonferroni as post-test where appropriate (Graph-
Padsoftware, San Diego,CA,USA). Differenceswereconsideredstatistically
significant with a P-value of ,0.05.
3. Results
3.1 Blood pressure changes and
Ach-induced response following ACE
inhibition
Animals were treated daily by oral gavage administration (vehicle,
S-zofenopril, and enalapril), and SBP was monitored. SHRs treated
with vehicle showed a significant increase in SBP compared with
WKY rats (Figure 2A, P, 0.001). Both S-zofenopril and enalapril signifi-
cantly lowered SBP in SHRs compared with the vehicle group (Figure 2A,
P, 0.001). S-zofenopril was significantly more effective when
compared with enalapril (167.5+2.5 vs. 178.8+4.6 mmHg, P,
0.05, n ¼ 10). Both drugs produced over 90% inhibition of ACE activity
(see Supplementary material online, Figure S1). Hypertensive animals
show an increased ACE expression in both aorta and carotid. Both
S-zofenopril and enalapril mitigated the increase in tissue ACE expres-
sion in aorta (Figure 2B, P, 0.01), but only S-zofenopril was effective
on ACE expression in carotid homogenates harvested from hyperten-
sive animals (Figure 2C, P, 0.05). Experiments were performed by
using aorta and carotid arteries harvested from rats at the end of treat-
ments, and their response to Ach was assessed in the isolated organ bath
system. Ach-induced relaxation was significantly impaired in SHRs com-
pared with WKY rats in both aorta (Figure 3A, P, 0.001) and carotid
(Figure 3C, P, 0.001). S-zofenopril treatment restored the Ach-induced
vasodilatation in both vessels (Figure 3B, P, 0.001 and Figure 3D,
P, 0.001). Enalapril did not significantly modify the vascular response
to Ach in both vessel types.
3.2 H2s pathwaymodulation in aorta and
carotid following in vivo S-zofenopril
treatment
Reduction in H2S levels has been associated with the development of
hypertension in this rat strain, as reported by others.31,32 Therefore,
we questioned whether prolonged ACE inhibition with enalapril or
S-zofenopril could affect the H2S pathway. We first assessed CSE expres-
sion by western blot analysis in aorta and carotid samples harvested from
treated animals. We found, as already reported in the literature,31,32 that
Figure 2 Blood pressure and ACE expression following ACEi treatment. (A) Blood pressure values (SBP, mmHg) following 2-weeks treatment with
S-zofenopril (S-ZOF) or enalapril (ENA) in SHRs and WKY rats. Data are expressed as mean+ SEM for n ¼ 10. * vs. WKY vehicle, P, 0.001; # vs.
SHR vehicle, P, 0.001; 8 vs. SHR ENA, P, 0.05. (B) Expression of ACE in aortic tissue harvested from WKY rats or SHRs, following ACEi treatment.
* vs. WKY vehicle, P, 0.01; # vs. SHR vehicle, P, 0.01. (C ) Expression of ACE in carotid tissue harvested from WKY rats or SHRs, following ACEi treat-
ment. * vs. WKY vehicle, P, 0.01; # vs. SHR vehicle, P, 0.05. Forty microgram of total protein was loaded per each lane, and the target protein band
intensity was normalized with the housekeeping protein b-actin. Blots are representative of three different experiments. Optical density is expressed
as arbitrary units (mean+ SEM).
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Figure 3 Functional reactivity in vascular tissue harvested from WKY rats treated with vehicle (open square, dashed line) and SHRs treated with vehicle
(inverted triangle), S-zofenopril (closed square, S-ZOF), or enalapril (triangle, ENA). (A) Ach-induced vasorelaxation in aortic rings is reduced in SHRs
compared with WKY, P, 0.001. (B) Ach-induced vasorelaxation is restored after S-zofenopril, but not enalapril, treatment, P, 0.001. (C) Ach-induced
vasorelaxation in carotid rings is reduced in SHRs compared with WKY rats, P, 0.001. (D) Ach-induced vasorelaxation is restored after S-zofenopril, but
not enalapril, treatment, P, 0.001. Ach-induced response is expressed as % of relaxation (mean+ SEM for n ¼ 6). * vs. WKY vehicle; # vs. SHR vehicle.
Figure 4 Biochemical analysis of the H2S pathway following S-zofenopril or enalapril treatment. (A) Expression of CSE protein levels in aorta lysates.
(B) Expression of CSE protein levels in carotid lysates. Forty microgram of total protein was loaded per each lane, and b-actin has been used as loading
control. Blots are representative of three different experiments. Optical density is expressed in arbitrary units (mean+ SEM) and normalized to b-actin ex-
pression levels as the housekeeping gene. * vs. WKY vehicle, P, 0.05; # vs. SHR vehicle, P, 0.05. (C) H2S production rate in aorta harvested from WKY rats
and SHRs treated with vehicle, S-zofenopril, or enalapril, after 40-min incubation in the presence of L-cysteine as substrate. (D) H2S production rate in carotid
harvested from WKY rats and SHRs treated with vehicle, S-zofenopril, or enalapril, after 40-min incubation in the presence of L-cysteine as substrate. (E) H2S
levels determination in plasma samples. Data are expressed as mean+ SEM for n ¼ 6. * vs. WKY vehicle, P, 0.05; # vs. SHR vehicle, P, 0.05.
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expression of CSE in aorta samples was significantly lower in untreated
SHRs compared with WKY rats (Figure 4A, P, 0.05). Treatment with
S-zofenopril, but not enalapril, restored CSE expression in SHRs bringing
back it to WKY level (Figure 4A, P, 0.05). Interestingly, CSE expression in
carotid arteries of SHR was significantly higher than in WKY. Neither
S-zofenopril nor enalapril significantly altered CSE expression in carotid
arteries (Figure 4B, P, 0.05). Furthermore, CBS and 3MST expression
were not modified by treatments (see Supplementary material online,
Figures S2 and S3, respectively).
Further analysis provided measurements of H2S levels in both aorta and
carotidusing amethyleneblue-basedassay.As already reported,H2S levels
within theaorta (Figure4C) and thecarotid (Figure4D)ofSHR animalswere
lower than the content measured in WKY. S-zofenopril restored H2S
levels to WKY levels in the aorta, as opposite to enalapril (Figure 4C, P,
0.05). There was no significant reduction in H2S levels between WKY
and SHR in the carotid. However, H2S levels were significantly enhanced
in the carotid harvested from SHRs treated with S-zofenopril (Figure 4D,
P, 0.05). Treatment with either S-zofenopril or enalapril did not affect
H2S production in WKY rats (see Supplementary material online, Figure
S4). Plasma H2S values observed were significantly lower in SHRs when
compared with WKY levels (Figure 4E, P, 0.05). S-zofenopril treatment
restored the H2S plasma concentration to WKY levels, while enalapril
did not modify H2S plasma levels (Figure 4E, P, 0.05).
3.3 Ex vivo functional study: L-cyst-induced
vasodilatation
In another set of experiments, a concentration–response curve to L-cys
was performed on both the aorta and carotid harvested from WKY rats
and SHRs at the end of treatments. L-Cys induces a concentration-
dependent vasodilation (0.1–1 mmol/L). The vasorelaxant effect
induced by L-cys on either aorta or carotid (Figure 5A andC, respectively)
harvested from SHRs was not significantly different from the response
obtained in WKY. However, S-zofenopril, but not enalapril treatment,
enhanced L-cys-induced vasodilatation in aorta and carotid rings
(Figure 5B and D, P, 0.05 and ,0.01, respectively).
3.4 S-zofenoprilat is an H2S donor
To evaluate whether S-zofenoprilat can act as an H2S donor, we mea-
sured the H2S release in cell-free assays. The evaluation was performed
by using two different analytical approaches, a fluorimetric and an
amperometric assay, since methylene blue assay was not chemically suit-
able for the detection of S-zofenoprilat-derived H2S. The fluorimetric
assay showed that S-zofenoprilat can spontaneously release H2S and
the fluorescent signal is significantly inhibited by haemoglobin (Hg), a
H2S scavenger (Figure 6A). In parallel, we also assessed that H2S
release by S-zofenoprilat occurred in a concentration-dependent
manner (Figure 6B), and that it occurs at a different rate compared
with other H2S donors (see Supplementary material online, Figure
S5D).29 To further confirm these data, we performed measurements
using an amperometric assay, confirming that H2S is released in solution,
triggered by addition of a nucleophilic agent, such as L-cys (Figure 6C).
In a separate set of experiment, we tested whether such H2S release
by S-zofenoprilat could directly induce vasodilation of aorta rings.
S-zofenoprilat elicits a concentration-dependent relaxation of the iso-
lated aorta harvested from both WKY rats and SHRs (Figure 6D). This
effect was inhibited by H2S pathway inhibitors (see Supplementary
Figure 5 L-Cys-induced vasorelaxation in aortic rings from WKY rats treated with vehicle (open square, dashed line) and SHRs treated with vehicle
(inverted triangle), S-zofenopril (closed square, S-ZOF), or enalapril (triangle, ENA). (A) L-Cys-induced vasorelaxation in aortic rings is slightly, though
not significantly, reduced in SHRs compared with WKY. (B) L-Cys-induced vasorelaxation is significantly enhanced in the aorta of S-zofenopril-treated
animals, P, 0.05. (C) L-Cys vasodilation does not significantly change between carotid rings harvested from SHRs compared with WKY rats.
(D) S-zofenopril treatment significantly increases vasorelaxation induced by L-cys administration in carotid rings, compared with vehicle-treated
animals, P, 0.01. Data are expressed as mean+ SEM for n ¼ 6. # vs. SHR vehicle.
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material online, Figure S5A–C). Conversely, enalaprilat had no direct
vasoactive effect when added in vitro to aorta rings (Figure 6D).
3.5 ACE involvement in H2S pathway
activation
Zofenopril(at) is a chiral molecule and S,S,S-zofenoprilat (Figure 1) is the
only active diasteroisomer used in therapy, inhibiting ACE with an IC50
of 10.9 nM. Conversely, S,S,R-zofenoprilat (IC50¼ 1700 nM)17 is not
used in clinic. In order to further define the net contribution of the thiol
group without affecting ACE activity, we treated SHRs in vivo with either
S- or R-zofenoprilat. As expected, only S-zofenoprilat significantly
lowered blood pressure (Figure 7A). Nevertheless, R-zofenoprilat,
despite the lack of an effect on blood pressure, was as active as
S-zofenoprilat in restoring the vascular response to Ach in both the
aorta (Figure 7B) and carotid (Figure 7C). The treatment with either
R- or S-zofenoprilat restored H2S levels in both the aorta (Figure 7D)
and carotid (Figure 7E), as well as in plasma samples (Figure 7F).
4. Discussion
Clinical evidence has accumulateddemonstrating that the sulfhydrylated
ACEi zofenopril exerts additional beneficial effects beyond ACE inhib-
ition.33–36 Zofenopril is a highly lipophilic ACEi characterized by long-
acting tissue penetration and cardioprotective properties.8 Zofenopril
is considered a pro-drug, since its action is due to the active metabolite
S-zofenoprilat. It has a free thiol and, therefore, we tested the hypothesis
that the modulation of the H2S pathway could be involved.
The study has been performed in vivo by comparing zofenopril with a
non-sulfhydrylated ACEi also used in clinic, e.g. enalapril. Similar to zofe-
nopril, enalapril is a pro-drug that following oral administration is meta-
bolized in vivo to enalaprilat, its active form. To define the specific
contribution of H2S in zofenopril action, we used SHRs as a model of
hypertension. SHRs and their matched control WKY were treated
with zofenopril and enalapril at doses already known to cause a
maximal reduction in blood pressure and almost complete inhibition
of ACE in this animal model.37 As expected, both ACEis reduced
blood pressure as well as ACE expression in both aorta and carotid in
SHRs.38 Nevertheless, S-zofenopril was significantly more effective
than enalapril in lowering blood pressure in vivo, despite the same
extent of ACE inhibition (see Supplementary material online, Figure
S1).37,39 To investigate the involvement of the H2S pathway, we har-
vested carotid and aorta and assessed their ability to respond to acethyl-
choline ex vivo. Ach-induced vasorelaxation was significantly reduced in
both isolated aorta and carotid from SHRs compared with WKY rats fol-
lowing treatment with the vehicle. This impaired response was rescued
by zofenopril treatment in vivo, while enalaprilwas ineffective. Therefore,
both drugs inhibit ACE, lower blood pressure but only zofenopril exerts
a peripheral beneficial vascular effect. Nevertheless, even though the
dose used of enalapril causes the same reduction in ACE activity, it has
to be stated that the dose of enalapril used did not exert the same
blood pressure lowering effect. This could be a possible explanation
why enalapril, which has been shown in other experimental setting to
rescue vascular reactivity, did not reach statistical significance in our ex-
perimental conditions. This result implies that the vascular effect
exerted by zofenopril treatment involves an additional mechanism(s)
Figure 6 Free H2S release determination. (A) Time-dependent release of H2S by S-zofenoprilat (open square, 0.2 mmol/L) was detected using dibro-
mobinane (0.25 mmol/L) and fluorescence was measured every 2 min, P, 0.001. S-zofenopril (diamond, S-ZOF, 0.1 mmol/L) shows that no H2S release
and haemoglobin (closed square, Hg, 10 mmol/L) reduces the amount of H2S detected from S-zofenoprilat (S-ZAT), P, 0.01. Data are presented as
means+ SEM for n ¼ 4. * vs. control vehicle (open circle, CTR); # vs. S-ZAT. (B) H2S release from different concentration of S-zofenoprilat in Dulbecco’s
Modified Eagle Medium (DMEM), quantified again by using dibromobimane fluorimetric determination. (C) Amperometric measurement vs. time of H2S
release in aqueous buffer,P, 0.05. * vs. S-zofenoprilat. (D)Vasorelaxant effect of S-zofenoprilat (open square,S-ZAT) vs. enalaprilat (triangle, ENAT) in rat
isolated aortic rings harvested from WKY rats. Effect of S-zofenoprilat is also shown on aortic rings harvested from SHRs (closed square, S-ZAT). Data are
expressed as mean+ SEM for n ¼ 6. * vs. ENA; P, 0.001.
M. Bucci et al.144
Downloaded from https://academic.oup.com/cardiovascres/article-abstract/102/1/138/527763
by FACOLTA' DI LETTERE E FILOSOFIA user
on 22 January 2018
beyond ACE inhibition. One of the possible mechanisms involved could
be the inhibition of bradykinin degradation. This activity promotes gen-
eration of endothelial nitric oxide. The contribution of NO throughACE
inhibition has also been clinically demonstrated.40 However, since this
effect is secondary to ACE inhibition and in our conditions both enalapril
and zofenopril doblock ACEat the sameextent, it is clear that zofenopril
has additional action(s) not linked to ACE inhibition. It has been already
shown that expression of CSE and H2S plasma levels are reduced in
SHRs.31,32 In line with these data, we did find a similar pattern in SHRs
treated with the vehicle. However, analysis of the tissue harvested
from the treated rats showed that, zofenopril, but not enalapril, restored
CSE expression and H2S levels. In addition, H2S plasma levels were also
re-established after zofenopril treatment. These data imply that, follow-
ing in vivo administration of zofenopril, activation of L-cys/H2S pathway
occurs within the vessels, which in turn restores Ach response. This hy-
pothesis is further sustained by the evidence that L-cys-induced vasodila-
tion was significantly enhanced exclusively following zofenopril
treatment. In summary, in SHR animals, the in vivo treatment with zofe-
nopril restores (i) Ach-induced relaxation, (ii) tissue and plasma H2S
levels, and (iii) CSE expression and enhancement of the response to
L-cys in both vessel types analysed.
Therefore, the active metabolite S-zofenoprilat positively modulates
the H2S pathway within the vessel wall. Next, we questioned whether
S-zofenoprilat could per se release H2S. In order to answer this question
and to further demonstrate that zofenopril additional effects do involve
H2S, we employed two different cell-free assays. Indeed, the widely used
methylene blue-based colorimetric assay could not be employed to
measure direct H2S release since S-zofenoprilat interferes when it is dir-
ectly added to the assay solution. Therefore, we utilized two different
approaches by using both fluorimetric- and amperometric-based
assays. Both assays clearly demonstrated that S-zofenoprilat releases
H2S. In the assay performed with the fluorescent probe, S-zofenoprilat,
but not zofenopril, released H2S. The fluorescent signals are significantly
inhibited by haemoglobin. The amperometric assay confirmed that
S-zofenoprilat slowly releases H2S in solution and this effect is further
increased by adding L-cys. The use of L-cys in the assay did not only
stem from the idea that H2S release from S-zofenoprilat is facilitated
by nucleophilic substances; it was also based on the observation that
the metabolism of S-zofenoprilat involves cysteine conjugation, as
demonstrated by using radiolabelled zofenopril.17 In order to confirm
data obtained in cell-free assays, we tested whether S-zofenoprilat
could relax rat aorta in vitro. Addition of cumulative concentration of
S-zofenoprilat, but not enalaprilat, on isolated aorta rings induced relax-
ation of vascular tissue in a concentration-dependent manner, further
demonstrating that S-zofenoprilat can release hydrogen sulfide and gen-
erate H2S-dependent vasorelaxation (see Supplementary material
Figure7 Changes in blood pressure, Ach-induced response, and biochemical analysis of H2S pathway followingR- or S-zofenoprilat treatment. (A) Blood
pressure values (SBP, mmHg) following 2-weeks treatment with S-zofenoprilat (S-ZAT) or R-zofenoprilat (R-ZAT) in SHRs. Data are expressed as
mean+ SEM for n ¼ 10. * vs. SHR vehicle, P, 0.01. (B) Functional reactivity in vascular tissues harvested from SHRs treated with vehicle (open
square, dashed line), S-zofenoprilat (closed circle, S-ZAT), or R-zofenoprilat (diamond, R-ZAT). Reduced Ach-induced vasorelaxation observed in
aortic rings from SHRs was restored following S-zofenoprilat or R-zofenoprilat treatment, P, 0.01. (C) Impaired Ach-induced vasorelaxation shown in
carotid rings from SHRs is restored after S- or R-zofenoprilat treatment, P, 0.001. Ach-induced response is expressed as % of relaxation
(mean+ SEM for n ¼ 6). * vs. SHR vehicle; # vs. SHR S-ZAT. (D) H2S production rate in aorta harvested from WKY rats and SHRs treated with
vehicle, S-zofenoprilat, or R-zofenoprilat, after 40-min incubation in the presence of L-cysteine as substrate. (E) H2S production rate in carotid harvested
from WKY rats and SHRs treated with vehicle, S-zofenoprilat, or R-zofenoprilat, after 40-min incubation in the presence of L-cysteine as substrate. (F) H2S
level determination inplasma samples. Data areexpressedasmean+ SEMforn ¼ 6.* vs. WKYvehicle, P, 0.05;# vs. SHR vehicle, P, 0.01 forS-ZATand
P, 0.001 for R-ZAT, respectively.
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online, Figure S5). Therefore, the in vivo treatment with zofenopril brings
about a tonic pulse of H2S, e.g. slow release within the cellular environ-
ment, where the ACE resides, leading to the beneficial vascular effects
described above. The vascular effects observed are in line with the
finding that zofenopril exerts a preferential inhibition on tissue ACE
rather than on the plasma isoform.7 In other words, S-zofenoprilat
reaches its target, e.g. tissue ACE, and releases H2S within the vascular
cells, thus operating a site-directed local delivery.
Zofenopril has active chiral centres and the isomer used in therapy is
the S-isomer that, leading to the formation in vivo of S-zofenoprilat, inhi-
bits ACE with an IC50 10.9 nM.
17 In order to further strengthen our find-
ings regarding the role of H2S in the action of zofenopril, we dosed SHRs
with either the R- or S-diastereoisomer of zofenoprilat. As expected,
R-zofenoprilat treatment did not reduce blood pressure in SHRs as op-
posite to S-zofenoprilat. However, when we performed the study on rat
carotid and aorta from SHR, we found that the Ach-induced vasorelaxa-
tion was equally rescued by both R- and S-zofenoprilat. Therefore,
the R-form, devoid of ACE inhibitory action, can still act at the vessel
level through the H2S pathway. This hypothesis is further sustained
by the finding that H2S levels found in tissues and plasma of
R-zofenoprilat-treated animals were identical to the ones observed in
the S-zofenoprilat-treated group. Thus, the modulation of the H2S
pathway by zofenopril represents an additional beneficial mechanism
unrelated to ACE inhibition. On the clinical side, it is important to
point out that zofenopril, but not ramipril or atenolol, improves flow-
mediated dilation.10 Interestingly, this action by zofenopril did not
involve NO, but was ascribed to a generic antioxidant action linked to
the thiol group of S-zofenoprilat. On the basis of our data, we can
now suggest that such action can be ascribed to stimulation of the H2S
pathway, rather than to an antioxidant property, since it is well known
that antioxidant do not work in this clinical setting.10
In conclusion, we show that the extra-beneficial effects described in
the literature for zofenopril over ACE inhibition3,7 –10,12 involve the
L-cys/H2S pathway. Overall, these findings confirm that H2S plays an im-
portant role in cardiovascular homeostasis and provideproofof concept
for the development of H2S-releasing therapeutic agents in cardiovascu-
lar disease therapy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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